Allitia DiBernardo, MD

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Patient-Reported Outcomes in Major Depressive Disorder With Suicidal Ideation: A Real-World Data Analysis Using PatientsLikeMe Platform

Objective: The current analysis utilized PatientsLikeMe (PLM) data to compare patient-reported experiences in patients with major depressive disorder (MDD) with suicidal ideation (MDSI) t...

Abigail Nash , MD, PhD;

Rachna Dayal , MSc;

Allitia DiBernardo , MD;

11/22/2019

Esketamine Nasal Spray for the Management of Treatment Resistant Depression in Adults: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?

Introduction: Esketamine nasal spray for management of treatment-resistant depression (TRD) was assessed using the metrics of number needed to treat (NNT), number needed to harm (NNH), an...

Jaskaran Singh , MD;

Allitia DiBernardo , MD;

Leslie Citrome , MD;

11/22/2019